New scan could spot hidden breast cancer spread
NCT ID NCT06335069
First seen Oct 01, 2025 · Last updated Jun 20, 2026 · Updated 36 times
Summary
This pilot study compares two types of PET scans in 20 women with ER-positive breast cancer. The standard tracer (18F-FDG) sometimes misses cancer spread in this subtype. The new tracer (68Ga-FAPI-46) targets a protein on tumor-supporting cells and may find more lesions. Researchers will see which tracer detects more cancer spots and whether taking biopsies of those spots is possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Maastricht University Medical Center+
RECRUITINGMaastricht, 5800, Netherlands
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-FAPI-46 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to more accurate staging of ER-positive breast cancer, helping doctors choose better treatments.
What could go wrong
This is a very small pilot study (20 people) that only tests if the new tracer finds more lesions. It does not yet prove it improves patient outcomes or survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.